On April 14, 2026, the Centers for Medicare & Medicaid Services (CMS) published the Interoperability Standards and Prior Authorization for Drugs Proposed Rule, representing a significant step toward modernizing prior...

New phase 3 data indicate that Takeda’s investigational orexin agonist, oveporexton, significantly improves daily functioning, cognition, and nighttime sleep in patients with narcolepsy type 1.

The integration allows clinicians to manage Onera studies directly within the Somnoware sleep lab management platform.

The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

The collaboration integrates data from the ProSomnus RPMO₂ into MonitAir’s platform to support longitudinal tracking.

Researchers have identified 10 molecular biomarkers in saliva that can detect 24-hour sleep deprivation with 94% accuracy, marking a significant step toward developing noninvasive roadside testing. This breakthrough stud...

BALTIMORE – Today, Dr. Fariha Abbasi-Feinberg became president of the American Academy of Sleep Medicine board of directors. She assumed the role during SLEEP 2026, the 40th annual meeting of the nation’s leading sleep m...

Season 8 | Episode 10 In this episode of Talking Sleep, host Dr. Seema Khosla welcomes Dr. Daniel Buysse and Dr. Todd Arnedt, both members of the AASM clinical practice guideline committee, to discuss the newly released...

AASM delegates represented the AASM at last week’s annual American Medical Association (AMA) meeting. Members participated in caucus meetings, including the Specialty and Service Society, the largest caucus in the AMA, r...

A study of 28 million days of health data reveals that fewer than 13% of individuals consistently meet both sleep and physical activity guidelines, suggesting that high-quality sleep is a primary driver of next-day movem...